Table 2 Summary of toxicities attributed to CAR-T cells*

CTCAE v4.0 AE category	AE detail	Arms 1 and 2 (ICT) N = 20	Arm 3 (ICV) N = 11		Arm 4 (Dual) N = 12		Arm 5 (Dual Tn/mem) N = 22
CTCAE v4.0 AE category	AE detail	Grade 3^ No. (%)	Grade 3 No. (%)	Grade 4 No. (%)	Grade 3 No. (%)	Grade 4 No. (%)	Grade 3^ No. (%)
Gastrointestinal disorders	Nausea	0	1 (9)	0	2 (17)	0	0
	Vomiting	1 (5)	0	0	2 (17)	0	0
General disorders and administration site conditions	Fatigue	1 (5)	1 (9)	0	0	0	0
General disorders and administration site conditions	Gait disturbance	0	0	0	1 (8)	0	0
Investigations	Alanine aminotransferase increased	0	0	0	0	0	1 (5)
Investigations	Lymphocyte count decreased	2 (10)	0	0	0	0	0
Metabolism and nutrition disorders	Hyponatremia	0	0	0	0	0	1 (5)
Musculoskeletal and connective tissue disorders	Back pain	0	0	0	0	0	1 (5)
	Neck pain	0	0	0	0	0	1 (5)
	Generalized muscle weakness	0	0	0	1 (8)	0	0
Nervous system disorders	Ataxia	0	0	0	0	0	1 (5)**
	Depressed level of consciousness	0	1 (9)	0	0	0	0
	Dysphasia	1 (5)	1 (9)	0	0	0	0
	Edema cerebral	0	0	1 (9)	0	1(8)	0
	Encephalopathy	0	0	0	1 (8)**	0	0
	Headache	3 (15)	1 (9)	0	3 (25)	0	2 (9)
	Hydrocephalus	0	1 (9)	0	0	0	1 (5)
	Nervous system disorders—left side Hemiparesis	0	0	0	1 (8)	0	0
	Peripheral motor neuropathy	0	1 (9)	0	0	0	0
Vascular disorders	Hypertension	2 (10)	4 (36)	0	1 (8)	0	2 (9)

^*Events of grade 3 or higher, according to the NCI Common Toxicity Criteria, with possible or higher attribution to CAR-T cell administration while on protocol therapy are reported.
^{^}No events of grade 4 or higher with possible or higher attribution to CAR-T cell administration while on protocol therapy were observed on arms 1, 2 or 5.
^**Events (grade 3 or higher) that were probably attributed to CAR-T cell administration while on protocol therapy.

Quick links

Search